Ionis Pharmaceuticals (IONS) EBT Margin (2009 - 2026)

Ionis Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 42.31% for Q2 2026.

• In Q2 2026, EBT Margin fell 6964.0% year-over-year to 42.31%; the TTM figure through Jun 2026 stood at 83.12% (down 5399.0% YoY), while the FY2025 annual figure was 40.39%, up 2494.0% from the prior year.
• EBT Margin for Q2 2026 stood at 42.31%, up from 184.62% in the prior quarter.
• The five-year high for EBT Margin was 27.33% in Q2 2025, with the low at 184.62% in Q1 2026.
• The 5-year median for EBT Margin is 62.21% (2024), against an average of 67.62%.
• The sharpest annual moves came in 2022 and 2025: EBT Margin plunged 8045 bps in 2022, then jumped 5672 bps in 2025.
• Ionis Pharmaceuticals' EBT Margin stood at 29.52% in 2022, then surged by 96 bps to 1.08% in 2023, then sank by 4295 bps to 47.53% in 2024, then tumbled by 137 bps to 112.87% in 2025, then soared by 63 bps to 42.31% in 2026.
• Business Quant data shows IONS's EBT Margin at 42.31% in Q2 2026, 184.62% in Q1 2026, and 112.87% in Q4 2025.